Day: May 2, 2024

Sales were a record at $5.07 billion; organic sales increased 1% Segment operating margin was 21.5%, or a record 24.7% adjusted, an increase of 150 basis points EPS were $5.56, or a record $6.51 adjusted, an increase of 10% Company increases outlook for segment operating margin and EPS 2024 Investor Meeting scheduled for May 16 at 2 p.m. Eastern time CLEVELAND, May 02, 2024 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today reported results for the fiscal 2024 third quarter ended March 31, 2024. Sales were $5.07 billion compared with $5.06 billion in the third quarter of fiscal 2023. Net income was $726.6 million compared with $590.9 million in the prior year quarter. Adjusted net income was $850.7 million, an increase of 10% compared with $771.9 million in the...

Company Increases Full-Year 2024 Guidance MIAMI, May 02, 2024 (GLOBE NEWSWIRE) — Laureate Education, Inc. (NASDAQ: LAUR), which operates five higher education institutions across Mexico and Peru, today announced financial results for the first quarter of 2024. First Quarter 2024 Highlights (compared to first quarter 2023): New enrollments increased 1%. Total enrollments increased 5%. On a reported basis, revenue increased 10% to $275.4 million. On an organic constant currency basis1, revenue increased 1% and was unfavorably affected by intra-year timing of semester start dates for certain programs as compared to the prior-year period. Operating income for the first quarter of 2024 was $11.1 million, compared to operating income of $15.6 million for the first quarter of 2023. Net loss for the first quarter of 2024 was $(10.8) million,...

TORONTO, May 02, 2024 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX: STCK and STCK.WT) today announced its financial results for the quarter ended March 31, 2024. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary: As at March 31, 2024, Book Value per Share (BVpS) of the Company was $11.03, compared with $10.91 as at December 31, 2023. Stack Capital increased its exposure to Locus Robotics through a share-swap transaction issuing 273,501 Stack Capital common shares, at $11.30 per share, which closed on March 4, 2024. The Company invested US$8 million into Canva, Inc., a collaborative all-in-one visual design and communication platform, which closed on March 18, 2024. The investment in Canva represents $1.18 of the Book Value per Share. Canva...

MONTREAL, May 02, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2024 financial results on Thursday, May 9, 2024 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, May 9, 2024 Time: 8:30 a.m. ET Telephone: Toll Free: 1-800-836-8184 or International 1-289-819-1350 Webcast: www.knighttx.com or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay: An archived replay will be available for 30 days at www.knighttx.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty...

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects Court provides claim construction ruling in ongoing patent infringement lawsuit against Moderna; Court date scheduled for April 21, 2025 Strong financial position – expected cash runway extended through the second quarter of 2026 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people...

Q1 results in line with expectations; Reiterates annual guidance ATCHISON, Kan., May 02, 2024 (GLOBE NEWSWIRE) — MGP Ingredients, Inc. (Nasdaq: MGPI), a leading provider of branded and distilled spirits as well as food ingredient solutions, today reported results for the first quarter ended March 31, 2024. 2024 first quarter consolidated results compared to 2023 first quarter: Due to the Atchison distillery closure, sales decreased 15% to $170.6 million. Excluding the impact of the Atchison distillery in both periods, consolidated sales were in line with the prior year period. As expected, gross profit decreased 10% to $62.8 million, representing 36.8% of sales. Excluding the impact of the Atchison distillery in the current period, gross margin was 37.3%. Operating income decreased 30% to $28.9 million. Adjusted operating income...

– Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the ATTRibute-CM Phase 3 study of acoramidis at the American College of Cardiology Annual Scientific Sessions; additional detailed results from ATTRibute-CM are planned for presentation at 2024 medical meetings, including four abstracts accepted for the European Society of Cardiology Heart Failure conference and eleven abstracts accepted for the International Symposium on Amyloidosis in May 2024 – The Company believes there is potential to pursue Accelerated Approval for BBP-418 based on recent interactions with the FDA on the use of glycosylated alpha dystroglycan (αDG) levels as a surrogate endpoint; the FORTIFY Phase 3 trial of BBP-418 in limb-girdle...

Record first quarter revenues of $2.8 billion, up 4.9% compared to first quarter 2023 Operating income of $154 million, up 9.2% compared to first quarter 2023 Net earnings of $153 million or $3.87 diluted earnings per share New contract awards of $3.1 billion, resulting in backlog of $48.4 billion Company reaffirms previously issued financial guidance1 NEWPORT NEWS, Va., May 02, 2024 (GLOBE NEWSWIRE) — HII (NYSE: HII) reported first quarter 2024 revenues of $2.8 billion, up 4.9% from the first quarter of 2023, driven primarily by growth at its Mission Technologies segment. Operating income in the first quarter of 2024 was $154 million and operating margin was 5.5%, compared to $141 million and 5.3%, respectively, in the first quarter of 2023. The increases were primarily driven by higher segment operating income2 compared to...

– Strong Growth and Leasing Activity – – Successful Execution on RPT Realty Acquisition – – Board Declares Quarterly Dividend – – Updates 2024 Outlook – JERICHO, N.Y., May 02, 2024 (GLOBE NEWSWIRE) — Kimco Realty® (NYSE: KIM), a real estate investment trust (REIT) and leading owner and operator of high-quality, open-air, grocery-anchored shopping centers and mixed-use properties in the United States, today reported results for the first quarter ended March 31, 2024. For the three months ended March 31, 2024 and 2023, Kimco Realty’s net (loss)/income available to the company’s common shareholders per diluted share was ($0.03) and $0.46, respectively. First Quarter Highlights Produced Funds From Operations* (FFO) of $0.39 per diluted share. Generated 3.9% growth in Same Property Net Operating Income* (NOI) over the same period a...

– Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 Annual Meeting in June – – Randomized, controlled Phase 1B dose-expansion cohort in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) patients expected to initiate enrollment in the second quarter of 2024 – – Presented preclinical data at the 2024 American Association for Cancer Research (AACR) Annual Meeting, demonstrating the potential therapeutic utility of TRIM7 inhibition to prevent or reverse acquired resistance to immune checkpoint therapy – AUSTIN, TX and DURHAM, NC., May 02, 2024 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage...